At a glance
- Originator Merck & Co
- Class
- Mechanism of Action Cholecystokinin A receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Pancreatic disorders
Most Recent Events
- 22 Aug 2001 No-Development-Reported for Pancreatic disorders in USA (Unknown route)
- 04 Aug 1997 New profile
- 04 Aug 1997 Preclinical development for Pancreatic disorders in USA (Unknown route)